Novel immunomodulatory therapies in the treatment of multiple myeloma.
Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Kenneth C
KC
Anderson
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy / Q000639:trends*; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000276:immunology* / Q000628:therapy*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D013792:Thalidomide; D000077269:Lenalidomide